Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 44, n° 4
pages 638-642 (avril 2001)
Doi : 10.1067/mjd.2001.112360
Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment
 

Adrian Tanew, MD a, Tanja Kipfelsperger, MD a, Arno Seeber, MD b, Sonja Radakovic-Fijan, MD a, Herbert Hönigsmann, MD a
a Division of Special and Environmental Dermatology, Department of Dermatology, University of Vienna Medical School Vienna, Austria 
b Department of Dermatology, Donauspital/SMZ-Ost. Vienna, Austria 

Abstract

Background: Bath-PUVA treatment, originally established in Scandinavia, offers several advantages over oral PUVA and has become increasingly popular in recent years. Outside Scandinavia 8-methoxypsoralen (8-MOP) is the prevailing photosensitizer for this PUVA modality and is used arbitrarily in a wide range of concentrations. Up to the present, data are lacking on the impact of 8-MOP bath-water concentration on UVA dosimetry. Objective: We investigated the influence of increasing 8-MOP bath-water concentrations on photosensitivity in bath-PUVA treatment. Methods: Fifteen healthy volunteers without abnormal photosensitivity or recent exposure to ultraviolet radiation were included in an intraindividually controlled comparison study. In all volunteers the minimal phototoxic dose (MPD) was determined on the volar side of their forearms after immersion for 20 minutes in 4 different 8-MOP bath-water concentrations (0.5, 1, 2.5, and 5 mg/L). The correlation between 8-MOP concentration and photosensitivity (defined as the reciprocal value of the MPD) was analyzed by linear regression analysis. In addition, the time course of erythema formation and the UVA dose-erythema response curve was assessed for each psoralen concentration. Results: The median MPD and the 25%-75% interquartile were 5.7 J/cm2 (5.7-8), 4 J/cm2 (4-5.7), 2.8 J/cm2 (2.8-5.7), and 2 J/cm2 (2-2.8) at an 8-MOP concentration of 0.5, 1, 2.5, and 5 mg/L, respectively. Linear regression analysis revealed a significant correlation between 8-MOP bath-water concentration and photosensitivity (r = 0.98; P = .019). Bath-PUVA-induced erythema peaked after a median time interval of 3 days, with a range of 2 to 4 days. The slope of the UVA dose-erythema response curve was similar for all psoralen concentrations. Conclusion: UVA dose requirements in bath-PUVA treatment decrease linearly with increasing 8-MOP concentrations. A single MPD assessment at 72 hours after the UVA exposure is inappropriate for accurate determination of the patients' photosensitivity. The hazard of wrong UVA dosimetry is comparable at all psoralen concentrations. (J Am Acad Dermatol 2001;44:638-42.)

The full text of this article is available in PDF format.

 Reprint requests: Adrian Tanew, MD, Division of Special and Environmental Dermatology, Department of Dermatology, University of Vienna Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
 J Am Acad Dermatol 2001;44:638-42



© 2001  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline